Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
The Journal of Experimental Medicine|March 1, 1983
Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppressionC Uyttenhove, J Maryanski, T BoonThe Journal of Experimental Medicine|November 1, 1980
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic miceC Uyttenhove, J Van Snick, T BoonProceedings of the National Academy of Sciences of the United States of America|September 1, 1988
Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activityC Uyttenhove, R J Simpson, J Van SnickThe Journal of Experimental Medicine|April 1, 1988
T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factorC Uyttenhove, P G Coulie, J Van SnickEuropean Cytokine Network|July 10, 1999
Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPLS Silla, F Fallarino, T Boon, et al.Current Protocols in Immunology|April 25, 2008
The p815 mastocytoma tumor modelT F Gajewski, M A Markiewicz, C UyttenhoveJournal of Immunology (Baltimore, Md. : 1950)|April 15, 1996
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunizationT F Gajewski, F Fallarino, C Uyttenhove, et al.The Journal of Experimental Medicine|March 1, 1987
Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomasJ Van Snick, A Vink, S Cayphas, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1996
Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivoF Fallarino, C Uyttenhove, T Boon, et al.International Journal of Cancer|January 15, 1983
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variantsJ L Maryanski, M Marchand, C Uyttenhove, et al.Pageof 4